Skip to main navigation Skip to search Skip to main content

A Randomized Phase 2 Trial of Erlotinib With or Without PF-3512676 for the Treatment of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure of At Least One Prior Chemotherapy Regimen

Project: Research

Project Details

StatusFinished
Effective start/end date12/15/06 → 05/17/11

Funding

  • Pfizer Incorporated: $13,118.00